Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

 Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors-

-Transaction to add near-term commercial opportunity to Jazz's pipeline- 

-Transaction represents total cash consideration of approximately $935 million, or $8.55 per share-

https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-acquire-chimerix-further-diversifying-oncology-portfolio-302393029.html